

RESEARCH

Open Access



# The choice of reference chart affects the strength of the association between malaria in pregnancy and small for gestational age: an individual participant data meta-analysis comparing the Intergrowth-21 with a Tanzanian birthweight chart

George Mtove<sup>1\*</sup>, Daniel T. R. Minja<sup>1</sup>, Omari Abdul<sup>1</sup>, Samwel Gesase<sup>1</sup>, Kenneth Maleta<sup>2</sup>, Titus H. Divala<sup>2</sup>, Noel Patson<sup>2</sup>, Ulla Ashorn<sup>3</sup>, Miriam K. Laufer<sup>4</sup>, Mwayiwawo Madanitsa<sup>5</sup>, Per Ashorn<sup>6,7</sup>, Don Mathanga<sup>2</sup>, Jobiba Chinkhumba<sup>2</sup>, Julie R. Gutman<sup>8</sup>, Feiko O. ter Kuile<sup>9</sup>, Sofie Lykke Møller<sup>10</sup>, Ib C. Bygbjerg<sup>10</sup>, Michael Alifrangis<sup>11,12</sup>, Thor Theander<sup>11,12</sup>, John P. A. Lusingu<sup>1,11,12</sup> and Christentze Schmiegelow<sup>11,12</sup>

## Abstract

**Background:** The prevalence of small for gestational age (SGA) may vary depending on the chosen weight-for-gestational-age reference chart. An individual participant data meta-analysis was conducted to assess the implications of using a local reference (STOPPAM) instead of a universal reference (Intergrowth-21) on the association between malaria in pregnancy and SGA.

**Methods:** Individual participant data of 6,236 newborns were pooled from seven conveniently identified studies conducted in Tanzania and Malawi from 2003–2018 with data on malaria in pregnancy, birthweight, and ultrasound estimated gestational age. Mixed-effects regression models were used to compare the association between malaria in pregnancy and SGA when using the STOPPAM and the Intergrowth-21 references, respectively.

**Results:** The 10th percentile for birthweights-for-gestational age was lower for STOPPAM than for Intergrowth-21, leading to a prevalence of SGA<sub>STOPPAM</sub> of 14.2% and SGA<sub>IG21</sub> of 18.0%,  $p < 0.001$ . The association between malaria in pregnancy and SGA was stronger for STOPPAM (adjusted odds ratio (aOR) 1.30 [1.09–1.56],  $p < 0.01$ ) than for Intergrowth-21 (aOR 1.19 [1.00–1.40],  $p = 0.04$ ), particularly among paucigravidae (SGA<sub>STOPPAM</sub> aOR 1.36 [1.09–1.71],  $p < 0.01$  vs SGA<sub>IG21</sub> aOR 1.21 [0.97–1.50],  $p = 0.08$ ).

**Conclusions:** The prevalence of SGA may be overestimated and the impact of malaria in pregnancy underestimated when using Intergrowth-21. Comparing local reference charts to global references when assessing and interpreting the impact of malaria in pregnancy may be appropriate.

\*Correspondence: mtoveg2002@gmail.com

<sup>1</sup> Tanga Medical Research Centre, National Institute for Medical Research, P. O. Box, 210, Tanga, Tanzania  
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Keywords:** Malaria in pregnancy, Birthweight, Reference chart, Individual participant data meta-analysis

## Background

The World Health Organization (WHO) estimated that 11.6 million pregnant women in sub-Saharan Africa were exposed to malaria in 2020 [1]. Malaria in pregnancy (MIP) is associated with adverse pregnancy outcomes, such as small for gestational age (SGA) [2–4], with the worst consequences occurring after infection in the first and second trimesters, particularly among paucigravidae [2, 4, 5].

Small for gestational age is defined as a birthweight below a pre-defined cut-off for a specific sex and gestational age (GA), often the 10th percentile [6, 7]. Decreasing birthweight is associated with higher neonatal morbidity and mortality [8–12] as well as long-term complications, including cardio-metabolic diseases [13–15]. Thus, SGA is a commonly used outcome in clinical trials on interventions to prevent MIP. The choice of reference chart is important for an accurate diagnosis of SGA [7, 16, 17]. In randomized clinical trials evaluating the efficacy of malaria interventions for improving pregnancy outcomes, misclassification of adequate for gestational age (AGA) as SGA and vice versa may dilute the observed treatment effect.

The Intergrowth-21 birthweight chart (IG21) is a universally applicable reference developed based on the assumptions that in healthy (low-risk) pregnancies, all fetuses achieve a similar growth potential, irrespective of ethnic or geographical differences, and that maternal and paternal anthropometric characteristics do not influence birthweight [18]. However, the WHO multi-country [19] and the National Institute of Child Health and Development fetal growth [16] studies found significant ethnic and geographic differences in newborn's size. Furthermore, several other studies have indicated that local weight references surpass IG21 in terms of diagnostic accuracy of SGA and its association with poor pregnancy outcomes [20–27]. This suggests that the IG21 may not be appropriate for identifying SGA in all settings, as recently concluded by the International Federation of Gynaecology and Obstetrics (FIGO) [17].

In 2011, a local Tanzanian reference chart (STOPPAM) was developed using data from 583 healthy newborns [28] as a hybrid of fetal weights (until 38 weeks) and birthweights. Thus, the STOPPAM reference would represent the newborns' potential size while taking the ethnic/geographical differences into account. STOPPAM is the largest chart in East Africa using ultrasound to estimate GA and fetal weight while excluding all

newborns at high risk of poor fetal growth. Furthermore, the criteria used to define a healthy pregnancy were quite similar to IG21 (Additional file 1: Table S1) despite the differences in the construction of the two reference charts [29–34]. Other references from sub-Saharan Africa either did not use ultrasound for GA estimation and included malaria positive women [35] or were smaller than STOPPAM [36, 37].

In this individual participant data meta-analysis, the performance of the IG21 was compared to the STOPPAM reference in estimating the association between MIP and SGA.

## Methods

### Study design

This was a meta-analysis of individual participant data from studies in Tanzania and Malawi. The primary outcome was SGA defined as birthweight < 10th percentile based on IG21 or STOPPAM sex-specific references while the primary exposure was MIP.


The study hypothesized that IG21 would overestimate the prevalence of SGA and ultimately weaken the strength of the association between MIP and SGA.

### Search strategy and inclusion criteria

A literature search was performed through PubMed, Medline, the Cochrane Library, and EMBASE. The search terms were (“malaria in pregnancy” OR “plasmodium malaria”) AND (SGA OR birthweight OR “birth weight”). In addition, personal communication was made for unpublished studies identified through existing research network. The inclusion criteria were pregnancy-related studies from East and Central Africa with data on GA estimated using ultrasound, birthweight measured within 24 h post-delivery or adjusted if measured > 24 h, newborns' sex, and MIP.

### Study selection and data gathering

Two authors (GM and CS) selected potentially relevant studies according to the eligibility criteria after reviewing the abstracts or full texts (Fig. 1). Then, raw data were conveniently sought for ten studies in which the authors were part of a consortium working on improving pregnancy outcomes using intermittent preventive treatment of malaria in pregnancy (IPTp) (<https://www.improve-consortium.org/>). Eight authors agreed to collaborate,



and seven of them shared the individual participant data (Fig. 1).

**Study population**

The meta-analysis included all live-born singleton newborns without congenital malformation, and with birthweight measured within 24 h of birth or birthweights measured > 24 h if the original study teams had already adjusted them [38, 39], known sex and GA estimated using ultrasound. Exclusion criteria were: stillbirth, multiple pregnancies, congenital malformation, unadjusted weights measured > 24 h post-delivery, and missing data on birthweight, sex, and/or GA.

**Assessment of the risk of bias**

The quality of each study was evaluated by one author (GM) using the Cochrane tool for individually randomized trials [40] and the Newcastle–Ottawa scale for cohort studies [41], and focused on how data on birthweight and MIP were obtained.

**Statistical analysis**

Analysis was done using Stata software, version 16 (Stata Corp, Texas, USA). Continuous variables were described as a mean with standard deviation (SD) or a median with interquartile range (IQR). Categorical variables were summarized as proportions with 95% confidence intervals (CI). The percentiles (10th, 50th, and 90th), GA-specific birthweight z-scores, and the prevalence of SGA were compared for the IG21 and STOP-PAM references. In addition, SGA was stratified as low birthweight (LBW < 2.5 kg) and normal birthweight (NBW ≥ 2.5 kg).

MIP was defined as any positive test at any point during pregnancy (microscopy, malaria rapid diagnostic test (RDT), polymerase chain reaction (PCR), or placental histology). In all analyses, the malaria-negative control group was defined as never having had malaria detected on any test.

A one-stage approach was used to combine the individual participant data using a mixed-effects regression

model. The unadjusted and adjusted odds ratios (uOR and aOR) for SGA in relation to MIP were calculated using this model. The overall effect was obtained from the preceding mixed-effects regression and the study-specific effects were obtained by logistic regression. This was done separately for both references,  $SGA_{STOPPAM}$  and  $SGA_{IG21}$ , and the results graphically presented as forest plots.

The main model compared SGA and MIP. This was further stratified by gravidity (paucigravidae (1st and 2nd pregnancy) vs multigravidae) and the time of infection (malaria in the 1st and 2nd, all trimesters, or 3rd trimester only vs malaria-negative). In sensitivity analyses, data were restricted to (a) only HIV-negative women-newborn pairs, (b) exclusion of sub-patent infections (PCR positive, microscopy negative), past infections (RDT positive, microscopy negative), or only positive placental histology (negative microscopy, RDT and PCR), (c) exclusion of studies that only used RDT [38] or only used PCR to detect malaria [42], (d) exclusion of a study only testing symptomatic cases at antenatal visits (Gutman et al., unpublished), (e) exclusion of newborns with adjusted weight measured >24 h post-delivery, (f) exclusion of newborns with GA-delivery  $\leq 38$  weeks as the STOPPAM reference was generated based on fetal weights in addition to birthweight until this GA, (g) only  $SGA_{IG21}$ -AGA<sub>STOPPAM</sub>, (h) only  $SGA_{STOPPAM}$ -AGA<sub>IG21</sub>.

In addition, the inclusion criteria used in the STOPPAM and IG21 studies were applied to the cohort [28, 43] and the prevalence of SGA in the “low-risk” cohort was re-evaluated with the assumption that a SGA prevalence of 10% would indicate the reference as representative.

Potential confounders were tested in univariate analysis using a mixed-effects regression model and included GA at enrolment and delivery, gravidity, maternal age, hemoglobin level, mid-upper arm circumference, and body mass index (BMI) at enrolment, utilization of IPTp, treated bed net, and iron plus folic-acid supplements, the number of antenatal visits, and syphilis or HIV-positivity. Variables with p-values <0.2 in the univariate analysis were included in the multivariate model, and a step-wise backward elimination approach was used to obtain the final model, retaining confounders with a p < 0.1. A p-value < 0.05 was considered statistically significant.

$I^2$  statistics could not be estimated in the one-stage approach because residual variability is not reported under mixed-effects regression with binary outcomes [44]. Hence, the parameters were fitted as random effects in the model to account for between-study variations [44]. Furthermore, a two-stage IPD meta-analysis was performed to assess heterogeneity between studies using  $I^2$  statistics and to assess the robustness of the analyses.

### Publication bias

A funnel plot was used to evaluate publication bias. The trim and fill method and contour enhancement funnel plot were used to determine whether the asymmetry in the forest plot was due to a small study effect or factors other than publication bias.

## Results

### Search results

The seven studies covered 7,443 newborns (Fig. 1). Of these, 521 were excluded due to: stillbirth (n = 148), congenital malformation (n = 56), twin pregnancy (n = 72), or unadjusted birthweight measured >24 h post-delivery (n = 245). Of the 6922 remaining newborns, 610 were missing birthweight, sex, and/or GA, and 76 had GA > 42 + 6 weeks, which is above the range of the two references. Hence, 6,236 mother-newborn pairs were analysed.

### Study description

Among the included studies, two were prospective cohorts [28, 45], and five were randomized trials, including one partially blinded [46] and four open-label [38, 39, 42] (Gutman et al., unpublished) (Table 1). Women were enrolled from the 2nd trimester in four studies [39, 42, 46] (Gutman et al., unpublished) and from the 1st trimester in three studies [28, 38, 45]. All studies had malaria related objectives except for one study on lipid-based nutrient supplements [38]. All women in this study received routine IPTp with sulfadoxine-pyrimethamine. Malaria testing strategies varied between studies: only RDT [38]; only PCR [42]; microscopy and PCR [46]; RDT, microscopy and PCR [28, 45]; RDT, microscopy, PCR and placental histology [39]; or PCR, microscopy and RDT at enrolment and delivery visits, but during antenatal visits only symptomatic women were tested (Gutman et al., unpublished). Three studies enrolled only HIV-seronegative women [39, 42] (Gutman et al., unpublished). The remaining four included HIV-positive women as well [28, 38, 45, 46].

### The quality and characteristics of the included studies

Two randomized trials were graded as being of good quality; the other three were potentially at high risk of bias (Additional file 1: Table S2). The observational studies were considered to have low risk of bias (Additional file 1: Table S3).

The maternal and newborns' characteristics are presented in Table 1. The median (IQR) maternal age was 23

**Table 1** Characteristics of the analyzed mother-newborn pair

	Luntamo et al. [46]	Schmiegelow et al. [28]	Madanitsa et al. [39]	Ashorn et al. [38]	Divala et al. [42]	Moeller et al. [45]	Gutman et al. <i>Unpublished</i>	All
Maternal <sup>a</sup>								
Study period	2003–2006	2008–2010	2011–2013	2011–2012	2012–2014	2014–2016	2017–2018	2003–2018
Sample size	1,173	752	1,607	1,109	747	375	473	6,236
Study design	RCT	Prospective cohort	RCT	RCT	RCT	Prospective cohort	RCT	–
Study location	Malawi	Tanzania	Malawi	Malawi	Malawi	Tanzania	Malawi	Tanzania & Malawi
Inclusion criteria	No severe illness, 14–26 weeks	All Consenting women ≤ 24 weeks	HIV neg, Hb > 7 g/dl, no risk factor, 16–28 weeks	≥ 15yrs, no risk factor, 14–20 weeks	HIV negative, paucigravidae, 15–28 weeks	All Consenting women, 4–28 weeks	≥ 16yrs, HIV negative, no risk factor, ≤ 28 weeks	–
GA estimation method	Transabdominal ultrasound (CRL or HC) or HC	Transabdominal ultrasound (HC)	Transabdominal ultrasound (HC)	Transabdominal ultrasound (BPD, AC, FL)	Transabdominal ultrasound (HC)	Transabdominal ultrasound (CRL or HC)	Transabdominal ultrasound (HC)	–
GA at entry (wks)	20 (18–23)	19 (15–21)	21 (19–23)	17 (15–19)	21 (22–24)	10 (7–13)	20 (18–22)	17 (19–22)
Trimester at enrollment								
First (≤ 13 weeks)	0 (0.0%)	85 (11.3%)	0 (0.0%)	30 (2.7%)	0 (0.0%)	284 (75.7%)	0 (0.0%)	399 (6.4%)
Early second (14–21 weeks)	815 (69.5%)	554 (73.7%)	1,064 (66.2%)	1,079 (97.3%)	386 (51.3%)	81 (21.6%)	329 (70.0%)	4,251 (68.2%)
Late second (22–27 weeks)	358 (30.5%)	113 (15.0%)	444 (27.2%)	0 (0.0%)	329 (44.0%)	8 (2.1%)	127 (26.4%)	1,433 (23.0%)
Third (≥ 28 weeks)	0 (0.0%)	0 (0.0%)	99 (6.2%)	0 (0.0%)	35 (4.7%)	2 (0.5%)	17 (3.4%)	153 (2.5%)
Follow up schedule	Four-weekly intervals until 36 weeks and weekly thereafter	Enrolment, at week 26–28, 30–32, 36–38, sick and delivery visits	Every four to six weeks until sick and delivery visits	Enrolment, at week 32, 36 and delivery	At least once every four weeks until delivery	Enrolment, at week 11–14, 20–22, 26–28, 32–34, 37–39; sick and delivery visits	Four weekly until delivery and sick visit	–
Type of weighing scale	Spring scale (Super Samson, Salter-Brecknell, 50 g) or digital (SECA 834, Chas-mors Ltd, 10 g)	Digital scale (ADE, 10 g) or Fazzini spring (50 g) on few	Not specified	SECA 381 baby scale, Seca GmbH & Co)	Not specified	Digital scale (precision, 5–10 g; M107600, ADE)	Digital scale	–
Adjusted BW > 24 h after birth	0 (0.0%)	0 (0.0%)	76 (4.7%)	338 (30.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	414 (6.6%)
Type of malaria test	Microscopy or PCR	Microscopy or mRDT (Parascreen, Paracheck or ParahIT) PCR on all mRDT positive	Microscopy or mRDT (First Response Malaria pLDH/HRP2 Combo Test), PCR and placental histology	mRDT (Clearview Malaria Combo; British Biocell International Ltd)	PCR	Microscopy, mRDT(ParahIT or Car-eStart) and PCR <sup>b</sup>	Microscopy, mRDT (Paracheck) and PCR	–
Age (years)	24 (20–29)	26 (22–31)	21 (18–26)	25 (20–29)	21 (19–23)	27 (22–34)	23 (19–29)	23 (19–28)
MUAC (cm) <sup>c</sup>	25.2 (± 2.1)	26.1 (± 2.9)	ND	26.3 (± 2.5)	ND	28.2 (± 3.8)	26.3 (± 3.2)	26.1 (± 2.8)
Weight (kg) <sup>c</sup>	52.4 (6.3)	55.0 (± 10.2)	55.2 (± 5.4)	54.1 (± 8.0)	58.9 (± 8.1)	57.5 (± 11.6)	58.5 (± 10.0)	55.9 (± 8.5)
Height (cm) <sup>c</sup>	155.0 (± 5.5)	157.5 (± 5.8)	154.0 (± 5.0)	156.1 (± 5.6)	157.3 (± 5.7)	155.4 (± 5.8)	157.3 (± 6.2)	156.0 (± 5.7)
BMI (kg/m <sup>2</sup> ) <sup>c</sup>	21.8 (± 2.2)	22.2 (± 3.6)	23.3 (± 2.9)	22.0 (± 2.7)	23.8 (± 3.0)	23.7 (± 4.2)	23.7 (± 4.1)	22.8 (± 3.2)
Gravidity:								
Paucigravidae	477 (40.7%)	345 (45.9%)	993 (61.9%)	431 (38.9%)	746 (100.0)	106 (28.3%)	266 (56.5%)	3,364 (54.0%)
Multigravidae	696 (59.3%)	407 (54.1%)	612 (38.1%)	676 (61.1%)	0 (0.0)	269 (71.7%)	205 (43.5%)	2,865 (45.9%)

**Table 1** (continued)

	Luntamo et al. [46]	Schmiegelow et al. [28]	Madanitsa et al. [39]	Ashorn et al. [38]	Divala et al. [42]	Moeller et al. [45]	Gutman et al. Unpublished	All
HIV status:								
Positive	144 (12.3%)	39 (5.2%)	NA	147 (13.3%)	NA	10 (2.7%)	NA	340/3,409 (9.9%)
Negative	913 (77.8%)	656 (87.2%)	NA	952 (85.8%)	NA	357 (95.2%)	NA	2,878/3,409 (84.4%)
Missing	116 (9.9%)	57 (7.6%)	NA	10 (0.9%)	NA	8 (2.1%)	NA	191/3,409 (2.7%)
Syphilis positive	58 (5.0%)	ND	ND	ND	ND	ND	2 (0.4%)	60 (3.9%)
ITN use	839 (71.5%)	714 (95.0%)	1,605 (99.9%)	1,087 (98.4%)	565 (75.6%)	353 (94.1%)	223 (47.2%)	5,841 (86.1)
# ANC visits	NA	4 (4–5)	4 (3–4)	4 (3–5)	ND	7 (6–9)	4 (4–5)	4 (3–5)
# of IPTp doses	4 (2–4)	2 (2–2)	2 (1–4)	ND	ND	3 (2–4)	ND	2 (2–4)
Iron use	ND	698 (92.6%)	1,802 (99.0%)	ND	ND	370 (98.7%)	ND	2,903 (82.8%)
Ever anaemic	449 (38.3%)	458 (60.9%)	451 (28.1%)	312 (28.1%)	169 (23.5%)	161 (42.9%)	146 (30.9%)	2,146 (34.6%)
Hb (g/dl) <sup>c</sup>								
Enrolment	11.0 (1.9)	10.9 (1.7)	11.0 (1.5)	11.2 (1.6)	11.7 (1.3)	11.6 (1.4)	10.7 (1.3)	11.1 (1.5)
Delivery	11.3 (1.8)	10.7 (1.4)	11.8 (1.6)	ND	ND	11.2 (1.5)	11.8 (1.5)	11.4 (1.4)
Overall malaria positivity in pregnancy	168 (14.3%)	52 (6.9%)	1,214 (75.5%)	400 (36.1%)	114 (15.3%)	143 (38.1%)	141 (29.8%)	2,232 (35.8%)
Malaria positivity rate by diagnostic test:								
mRDT	ND	48/752 (6.4%)	337/1,607 (21.0%)	400/1105 (36.1%)	ND	142/375 (37.9%)	31/473 (6.6%)	958/4,316 (22.2%)
PCR	50/456 (11.0%)	ND	1,095/1,600 (68.4%)	ND	114/746 (15.3%)	125/375 (33.3%)	127/473 (26.9%)	1,511/3,650 (41.4%)
Slide	136/1,173 (11.6%)	33/752 (4.4%)	553/1,607 (34.4%)	ND	ND	90/375 (24.0%)	10/465 (2.1%)	822/4,372 (18.8%)
Placenta histology	ND	ND	400/1,607 (24.9%)	ND	ND	ND	ND	400/1,607 (24.9%)
Newborn <sup>a</sup>								
GA del, wks	39 (38–40)	40 (39–41)	38 (37–40)	40 (39–41)	39 (38–40)	40 (39–41)	39 (37–40)	39 (38–40)
Preterm	113 (9.6%)	23 (3.1%)	259 (16.1%)	56 (5.1%)	75 (10.1%)	17 (4.5%)	67 (14.2%)	616 (9.9%)
Sex = Male	594 (50.6%)	372 (49.2%)	846 (50.2%)	609 (48.8%)	369 (48.6%)	184 (49.1%)	267 (54.1%)	3,093 (49.6%)
BW (gm) <sup>c</sup>	2,967 (±462)	3,154 (±472)	2,936 (±428)	2,981 (±453)	2,910 (±393)	3,022 (±461)	2,988 (±410)	2,980 (±451)
LBW	109 (9.3%)	47 (6.3%)	173 (10.8%)	140 (12.6%)	91 (12.2%)	39 (10.4%)	40 (8.5%)	639 (10.3%)
SGA <sub>STOPPAM</sub> <sup>b</sup>								
Malaria	35/168 (20.8%)	11/52 (21.1%)	176/1,214 (14.5%)	88/400 (22.0%)	17/114 (14.9%)	29/143 (20.3%)	20/141 (14.2%)	376/2,232 (16.8%)
No malaria	150/1,005 (14.9%)	67/700 (9.6%)	43/393 (10.9%)	104/709 (14.7%)	90/632 (14.2%)	40/232 (17.2%)	16/332 (4.5%)	510/4,003 (12.8%)
Overall	185/1,173 (15.8%)	78/752 (10.4%)	219/1,607 (13.6%)	192/1,109 (17.3%)	107/747 (14.5%)	69/375 (18.4)	36/473 (7.6%)	886/6,235 (14.2)
SGA <sub>IG21</sub> <sup>b</sup>								
Malaria	35/168 (20.8%)	15/52 (28.2%)	187/1,214 (15.4%)	113/400 (28.3%)	19/114 (16.7%)	40/143 (28.0%)	24/141 (17.0%)	433/2,232 (19.4%)
No malaria	177/1,005 (17.6%)	114/700 (16.3%)	46/393 (11.7%)	146/709 (20.6%)	120/632 (19.0%)	59/232 (25.4%)	28/332 (8.0%)	690/4,003 (17.2%)
Overall	212/1,173 (18.2%)	129/752 (17.2%)	233/1,607 (14.5%)	259/1,109 (23.4)	140/747 (18.7%)	99/375 (26.4%)	52/473 (11.0%)	1,123/6,235 (18.0%)

RCT: randomized controlled trial, CRL: crown rump length, HC: head circumference, AC: abdominal circumference, FL: femur length, ND not done, MA not applicable, MUAC: mid upper arm circumference, BMI: body mass index, HIV: Human Immunodeficiency Virus, ITN: treated bed nets, ANC: antenatal care, IPTp: intermittent preventive treatment of malaria in pregnancy, Hb: hemoglobin, GA: gestational age, preterm: GA < 37 weeks, BW: birthweight, LBW: BW < 2.5 kg, SGA<sub>STOPPAM</sub>: small for gestational age using STOPPAM reference, SGA<sub>IG21</sub>: SGA using Intergrowth-21 reference, total is < 100% in case of missing data

<sup>a</sup> All results are number (%) or median (Interquartile range) unless stated otherwise

<sup>b</sup> Malaria species diagnostic polymerase chain reaction (PCR) was also done for all mRDT-positive samples and samples for those who were always mRDT negative collected at GA 26–28 weeks or at delivery

<sup>c</sup> mean (standard deviation)

(19–28) years, and >50% of the women were paucigravidae. Among the four studies including women with HIV, 10.0% (340/3,409) were HIV-seropositive. The cumulative malaria incidence varied from 6.9% to 75.5%, with an average of 35.6% for all studies. The median (IQR) GA at delivery was 39 + 0 (38 + 0–40 + 0) weeks, and 9.9% were born preterm. The mean (SD) birthweight was 2978 (451) grams, with 10.3% being LBW (<2500 g).

#### Birthweight percentiles and prevalence of SGA

The weight percentiles differed between the STOPPAM and IG21 references depending on GA (Additional file 2: Fig. S1). The 10th percentiles for the two references converged at a GA of 36 + 2 for boys and 38 + 1 for girls. The IG21 had a lower 10th percentile than the STOPPAM reference at earlier GA, with a mean difference of – 105 g for boys and –136 g for girls at GA 36 + 0. At later GA, the direction shifted, with the 10th percentile for IG21 being higher, resulting in a mean difference of +133 g for boys and +123 g for girls at GA 40 + 0 compared to the STOPPAM reference. A similar pattern was also observed for the 50th percentile, whereas the 90th percentile for the IG21 was higher compared to the STOPPAM reference throughout gestation (Additional file 2: Fig. S1). The mean (SD) birthweight z-score was – 0.14 (1.19) for the STOPPAM and – 0.42 (0.99) for IG21 reference (Additional file 3: Fig. S2).

The differences in the 10th percentile were reflected in the prevalence of SGA. Fewer newborns were SGA when using the STOPPAM compared to the IG21 reference (14.2% (95% CI: 13.4–15.1) vs 18.0% (95% CI: 17.1–19.0)),  $p < 0.001$  (Table 2) and the proportion of SGA varied with GA. Preterm, the prevalence of SGA was higher when using the STOPPAM reference ( $SGA_{STOPPAM}$  15.4% (95% CI: 12.6–18.3) vs.  $SGA_{IG21}$  7.0% (95% CI: 5.0–9.0)),  $p < 0.001$ . All preterm SGA newborns were also LBW (Additional file 1: Table S4). At term, the prevalence was higher when using the IG21 reference ( $SGA_{IG21}$  19.3% (95% CI: 18.2–20.3) vs.  $SGA_{STOPPAM}$  14.1% (95% CI: 13.2–15.0)),  $p < 0.001$  (Table 2). The excess proportion of  $SGA_{IG21}$  was especially among NBW-term newborns (Additional file 1: Table S4). When applying IG21 and STOPPAM inclusion criteria,  $SGA_{IG21}$  were 14.9% and 17.2%, whereas  $SGA_{STOPPAM}$  were 9.6% and 11.5%, respectively (Additional file 1: Table S5).

#### Association between MIP and SGA

The STOPPAM reference was more sensitive than the IG21 reference in detecting an association between MIP and SGA (STOPPAM: uOR 1.54 (95% CI: 1.30–1.82),

$p < 0.001$ ; aOR 1.30 (1.09–1.56),  $p = 0.004$ . IG21: uOR 1.38 (95% CI: 1.18–1.61),  $p < 0.001$ ; aOR 1.19 (1.00–1.40),  $p = 0.044$ ) (Fig. 2).

When only including newborns of paucigravidae women, the results were robust, with slightly higher uOR for  $SGA_{STOPPAM}$  than for  $SGA_{IG21}$  and the aOR was only significant when using the STOPPAM reference (Fig. 3).

The proportion of SGA was highest among newborns of women who had malaria in the 1st and/or 2nd trimester or in all three trimesters compared to malaria only in the 3rd trimester (Table 3). This was reflected in a strong association between MIP and SGA in these groups, both when using the STOPPAM reference (uOR 1.72 (1.41–2.10),  $p < 0.001$ ; aOR 1.45 (1.17–1.78),  $p = 0.001$ ) and the IG21 reference (uOR 1.62 (1.35–1.94),  $p < 0.001$ ; aOR 1.39 (1.14–1.69),  $p = 0.001$ ) (Fig. 4). Malaria infection during the 3rd trimester only was not significantly associated with SGA (Table 3).


#### Other sensitivity analyses

The performance of the STOPPAM and IG21 references was also assessed after stratifying for malaria testing strategies, birthweight adjustment,  $GA \leq 38$  weeks, or HIV-seropositivity. Overall, similar results on the performance of the two references in detecting the association between MIP and SGA were obtained when excluding: studies using only one type of diagnostic test (RDT or PCR) or only testing symptomatic cases during antenatal visits, newborns with adjusted birthweight, newborns with  $GA \leq 38$  weeks, and HIV-seropositive. When solely defining malaria as microscopy blood smear positive, the effect of malaria was not statistically significant for neither  $SGA_{STOPPAM}$  nor  $SGA_{IG21}$  (Additional file 1: Table S6, Additional file 4: Fig. S3).

The association between malaria and SGA was not significant for neither  $SGA_{IG21}$ - $AGA_{STOPPAM}$  (aOR 0.90 (0.67–1.20),  $p = 0.47$ ), nor  $SGA_{STOPPAM}$ - $AGA_{IG21}$  (aOR 1.02(0.62–1.69),  $p = 0.93$ ) (Additional file 1: Table S7).

Finally, a two-stage individual participant data meta-analysis was applied, which yielded similar trends for the STOPPAM (uOR 1.57 (1.25–1.96); aOR 1.21 (0.99–1.43)) and the IG21 reference (uOR 1.39 (1.14–1.69); aOR 1.12 (0.92–1.31)) (Additional file 5: Fig. S4).

The trim and fill funnel plots revealed no strong evidence of small study effects for neither STOPPAM ( $p = 0.10$ ) nor IG21 reference ( $p = 0.35$ ). Similarly, the contour-enhanced funnel plot indicated the distribution of studies in both contours with small and large p-values (Additional file 6: Fig. S5).



**Discussion**

Malaria can cause fetal growth restriction, preterm delivery, and SGA [2, 4, 5]. In this meta-analysis, the use of a local reference (STOPPAM) was more sensitive than a universal reference (IG21) in detecting a relationship between MIP and SGA. The effect was more pronounced among paucigravidae and following malaria infection in early pregnancy.

Malaria infection in early pregnancy is detrimental to fetal growth [2, 4, 5]. We likewise observed an increased risk of SGA after stratifying by early infections. The IG21 reference was less sensitive than STOPPAM in detecting

an association between MIP and SGA. However, this was by far outweighed by the greater impact of malaria in early pregnancy, and the association between MIP and SGA<sub>STOPPAM</sub> as well as SGA<sub>IG21</sub> was statistically significant.


The association between MIP and SGA was similar for only paucigravidae compared to all gravidae. However, the aOR for IG21 was not statistically significant, reflecting the smaller aOR for SGA<sub>IG21</sub> and the smaller sample size when including only paucigravidae. Similarly, the sample size was considerably reduced if malaria was only defined as microscopy positive. This resulted

**Table 2** Comparing the prevalence of small for gestational age among preterm, full term and all infants using the STOPPAM and the Intergrowth-21 references

Preterm (N = 616)			Full term infants (N = 5,620)			All infants (N = 6,236)		
SGA <sub>IG21</sub>	SGA <sub>STOPPAM</sub> , n (%)		SGA <sub>STOPPAM</sub> , n (%)			SGA <sub>STOPPAM</sub> , n (%)		
	Yes	No	Yes	No	Total	Yes	No	Total
Yes	43 (7.0)	0 (0.0)	745 (13.3)	336 (6.0)	1,081 (19.3)	788 (12.6)	336 (5.4)	1,124 (18.0)
No	52 (8.4)	521 (84.6)	47 (0.8)	4,492 (79.9)	4,539 (80.7)	99 (1.6)	5,013 (80.4)	5,112 (82.0)
Total	95 (15.4)	521 (84.6)	792 (14.1)	4,828 (85.9)	5,620 (100)	887 (14.2)	5,349 (85.8)	6,236 (100)

SGA<sub>STOPPAM</sub>: small for gestational age (SGA) using STOPPAM reference, SGA<sub>IG21</sub>: SGA using intergrowth-21 reference, Preterm: gestational age (GA) < 37 weeks, Full term: GA ≥ 37 weeks





in statistically insignificant results for both references despite microscopy positivity normally being stronger associated with SGA than PCR positivity.

The IG21 classified 6.0% of full-term newborns as SGA who were AGA based on the STOPPAM reference. These newborns could be constitutionally small but healthy. Misclassification of SGA may diminish the ability to detect an effect of MIP on SGA. Indeed, the uOR and aOR were close to 1 in this sub-group.

The study also revealed that 1.6% of newborns (99/6,236) were SGA<sub>STOPPAM</sub> but AGA<sub>IG21</sub>, with the majority being born preterm. The STOPPAM chart combines fetal weights and birthweights, whereas the IG21 chart is exclusively based on birthweight. Preterm newborns tend to be smaller than fetuses staying in the womb at the same GA [28, 47, 48]. This may explain the lower 10<sup>th</sup> percentile for IG21 at preterm GA, resulting in a higher proportion of preterm newborns being classified as AGA on IG21. The association between MIP and SGA<sub>STOPPAM</sub>-AGA<sub>IG21</sub> was statistically insignificant. This may partially be explained by the very small number of SGA<sub>STOPPAM</sub>-AGA<sub>IG21</sub>.

The findings from this meta-analysis support prior studies showing that an international reference may overestimate SGA in a high-risk population with increased exposure to multiple causes of poor fetal growth, including infections like malaria and poor nutrition [20, 49] while underestimating it in low-risk populations [50]. Several other studies [22, 23, 50, 51] found differences between local and global references. The results of this and previous studies [20–23, 49–51] strengthen the importance of having a reference chart derived from a local population, thereby accounting for geographical and ethnic differences. The FIGO position paper supports this approach [17].

The study findings have implications in research settings where the correct diagnosis of SGA is important to accurately estimate the effect of malaria interventions for improving pregnancy outcomes. When SGA is misclassified, particularly in randomized clinical trials using composite endpoints that include SGA, the treatment effect can be weakened, especially when the proportionate reduction of adverse pregnancy outcome is small.

**Table 3** Association between malaria infection and small for gestational age, stratified by timing of infection


Timing of infection <sup>a</sup>	STOPPAM reference					Intergrowth-21 reference						
	N	SGA <sub>STOPPAM</sub> n (%)	uOR	95% CI	P	SGA <sub>I21</sub> n (%)	uOR	95% CI	P	aOR <sup>c</sup>	95% CI	P
Never infected	3,371	420 (12.5)	1	-	-	579 (16.9)	1	-	-	-	-	-
1st/2nd trimester	1,214	205 (16.9)	1.60	1.31–1.96	<0.001	250(20.6)	1.52	1.27–1.83	<0.001	1.30	1.07–1.58	0.009
1st/2nd/3rd trimesters	258	52 (20.2)	2.37	1.65–3.41	<0.001	56 (21.8)	2.18	1.54–3.10	<0.001	1.68	1.16–2.43	0.006
3rd trimester only	646	102 (15.8)	1.47	1.14–1.91	0.003	108(16.7)	1.19	0.93–1.52	0.17	1.07	0.83–1.38	0.62

The pooled uOR (n = 5489) and aOR (n = 5208) were obtained using mixed effect model in the one stage individual participant data meta-analysis excluding a study by Divala et al. because malaria infection was only documented at inclusion and delivery

<sup>a</sup> stratified malaria into 3 groups, whereas in Fig. 4 we pooled together 1<sup>st</sup>/2<sup>nd</sup> and 1<sup>st</sup>/2<sup>nd</sup>/3<sup>rd</sup> and excluded 3<sup>rd</sup> trimester only to allow for the forest plot, 1<sup>st</sup> trimester: ≤ 13 weeks, 2<sup>nd</sup> trimester: 14–27 weeks, 3<sup>rd</sup> trimester: ≥ 28 weeks, SGA<sub>STOPPAM</sub>: Small for gestational age (SGA) using STOPPAM reference, SGA<sub>I21</sub>: SGA using Intergrowth-21 reference, uOR unadjusted odds ratio, aOR: Adjusted odds ratio

<sup>b</sup> adjusted for body mass index, gravidity, gestational age at enrolment, HIV, and haemoglobin at enrolment

<sup>c</sup> adjusted for gestational age at delivery in addition to the confounders for aOR<sup>b</sup>, CI Confidence interval, malaria was defined as positive slide or malaria rapid test or polymerase chain reaction



The difference in the 10th percentile between the two references is critical. The study revealed a mean difference in the 10th percentiles between STOPPAM and IG21 of 133 g for boys and 123 g for girls at GA 40+0 weeks. This may affect a study’s ability to detect an impact on SGA given the relatively small difference in mean birthweight resulting from malaria interventions, such as insecticide-treated nets or IPTp with sulfadoxine-pyrimethamine (+2.5 to 3%) [52, 53].

It is important to determine which reference is the most representative for the study population. Both the IG21 and the STOPPAM reference were based on low-risk populations. Therefore, the IG21 and STOPPAM criteria were applied to limit the cohort to the healthy/low-risk population, expecting the prevalence of SGA to be close to 10% on a representative reference. However, SGA<sub>IG21</sub> was 15% and 17% when applying the IG21 [43] and STOPPAM [28] criteria but only 9.6% and 11.5% for SGA<sub>STOPPAM</sub> respectively. This indicates that the study population is more similar to the STOPPAM reference and the higher proportion of SGA when using IG21 is likely an overestimation.

There are differences in the construction of the two references, with the STOPPAM reference being a hybrid chart including fetal weights until GA 38 and IG21

being a pure birthweight chart. A levelling of growth was observed in late pregnancy on the STOPPAM reference. The Hadlock formula was used for estimating fetal weight, which may be slightly overestimated when applied in an African population [54]. This could explain the observed levelling. However, the flattening of the percentiles could also represent a true waning of growth as observed in other populations in late pregnancy [55, 56]. If restricting the analyses to newborns with GA >38 weeks, and both references thereby constructed based on birthweights, a similar higher association between MIP and SGA<sub>STOPPAM</sub> compared to MIP and SGA<sub>IG21</sub> was observed. This supports the use of the STOPPAM reference despite the different methodology compared to IG21.

The strength of this analysis is the use of a large number of individual participants from a similar geographical area, all with GA estimated by ultrasound. The quality of birthweight was optimized by excluding newborns with unadjusted birthweight measured >24 h post-delivery, twin deliveries, congenital malformations, and stillbirths. However, there are several limitations. First, the analysed studies used different methodologies for malaria diagnosis, with only one study including placenta histology and some studies using either only one type of malaria test or

testing symptomatic cases only. This has a potential for misclassification bias. Except for the analyses on microscopy positivity (Additional file 1: Table S6), analysis based on a single test was not performed due to the small sample size that would have reduced the study power; however, the sensitivity analyses stratified by malaria diagnosis methodology gave robust results. This reassures that the results were not significantly affected. Furthermore, some studies adjusted birthweight measured > 24 h while others did not report the precise time of measurement, allowing for birthweight adjustment. However, excluding all adjusted birthweights did not alter the results, thereby justifying including them to obtain as large a sample size as possible.

The analysis excluded newborns missing information on sex, GA, or birthweight, and those with unadjusted birthweight measured > 24 h post-delivery. These accounted for a small proportion (12%) of total newborns and thus are unlikely to have led to selection bias. Furthermore, these newborns were not different from included newborns with respect to malaria exposure and the main confounders though there were some differences with respect to maternal age, gravidity, and BMI (Additional file 1: Table S8). The study compared two reference charts which were developed using different methodologies. Intergrowth-21 was only based on birthweight while STOPPAM is a hybrid of birthweight and fetal weight; the latter may be prone to errors, especially at a later GA with the expected uncertainty on the fetal weight of  $\pm 10\%$ .

Finally, the analysis conveniently included studies that were part of the IMPROVE Consortium (<https://www.improve-consortium.org/>). The study aim was not to get a precise estimate of the association between MIP and SGA through a systematic review including all possible studies, but rather to investigate the impact of using one reference versus another. Data were not obtained for three eligible studies. Therefore, it can't be ruled out that this may have influenced the result, given the fewer studies for publication bias assessment.

## Conclusion

The higher birthweight percentiles at term for the IG21 reference may lead to an overestimation of SGA and an underestimation of malaria's potential impact on birthweight. When analysing the impact of malaria on pregnancy outcomes or trials of intervention to reduce malaria-associated fetal growth restriction, adding locally created reference charts to global references may be appropriate as they account for ethnic diversity and geographical differences.

## Abbreviations

SGA: Small for gestational age; AGA: Appropriate for gestational age; GA: Gestational age; MIP: Malaria in pregnancy; IG21: Intergrowth-21 birthweight reference chart; STOPPAM: Stop pregnancy associated malaria-fetal and birthweight reference chart; BMI: Body mass index; IMPROVE: Improving pregnancy outcome using intermittent preventive treatment of malaria in pregnancy.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12936-022-04307-2>.

**Additional file 1: Table S1.** Comparison of the Intergrowth-21 and STOPPAM standard charts. **Table S2.** Quality of studies using Cochrane's Risk of Bias 2 tool (ROB-2) for randomized trials. **Table S3.** Risk of Bias assessment by Newcastle scale for cohort studies. **Table S4.** Prevalence of small for gestational age by gestational age and birthweight. Table S5. Prevalence of small for gestational age when applying the inclusion criteria for each reference chart. **Table S6.** Sensitivity analysis for the association between malaria in pregnancy and SGA when using STOPPAM vs Intergrowth-21st reference. **Table S7.** association between malaria and small for gestational age for discordant groups. **Table S8.** Characteristics of analysed mother-newborn pairs vs excluded.

**Additional file 2: Figure S1.** Birth weight percentiles by sex and gestational age for STOPPAM vs. Intergrowth (IG21) references. The percentiles before and after 33 weeks for Intergrowth were merged, hence the bend in the 10th percentile.

**Additional file 3: Figure S2.** The birth weight z-scores comparing STOPPAM vs. Intergrowth (IG21) references. The dash line indicates the mean birthweight z-scores.

**Additional file 4: Figure S3.** Association between small for gestational age (SGA) and malaria in pregnancy excluding all HIV seropositive women. Panels A and B shows the unadjusted odds ratio (uOR) for SGA when using STOPPAM ( $SGA_{STOPPAM}$ ) and Intergrowth-21 ( $SGA_{IG21}$ ) references. Panels C and D shows the adjusted odds ratio (aOR).

**Additional file 5: Figure S4.** Two stage individual participant data meta-analysis on the association between malaria in pregnancy (MIP) and small for gestational age (SGA) using the STOPPAM ( $SGA_{STOPPAM}$ ) vs. the Intergrowth-21 reference ( $SGA_{IG21}$ ). uOR: unadjusted odds ratio in panels A and B, aOR: adjusted odds ratio in panels C and D controlling for body mass index, gravidity, gestational age at enrolment, HIV, and hemoglobin level at enrolment. In addition, adjusted for gestational age at delivery for  $SGA_{IG21}$ . CI: confidence interval, malaria was defined as positive slide or positive malaria rapid test or positive polymerase chain reaction or positive placenta histology, % Weights are from random effects analysis.

**Additional file 6: Figure S5.** Funnel plots for meta-analysis. The closed dots indicate the observed studies, panel A indicate the trim and fill funnel plot for STOPPAM ( $P = 0.10$ ) and panel B for Intergrowth-21 reference ( $P = 0.35$ ). The contour enhanced funnel plot for STOPPAM (panel C) and Intergrowth-21 (panel D) show the distribution of studies in both the small and large p-values contours, hence no publication bias.

## Acknowledgements

We are grateful to Prof. Thomas Scheike and Mr. Frederik Mølkjær Andersen at the Department of Biostatistics, Institute of Public Health, University of Copenhagen, Denmark for advice regarding the statistical approach.

## Author contributions

GM and CS conceived and designed the study. DTRM, OA, SG, KM, THD, NP, UA, MKL, MM, PA, DM, JC, JRG, FOTK, SLM, ICB, MA, TT, JPAL, and CS co-authored the original studies and provided the individual participant data for the meta-analysis. GM analysed the data, and drafted the original manuscript. All authors participated in the writing of the manuscript. All authors reviewed and approved the final manuscript. All authors read and approved the final manuscript.

## Funding

GM received financial support from the EDCTP2 programme and the MRC/DFID/Wellcome Trust's Joint Global Health Trials (JGHT) scheme to the Liverpool School of Tropical Medicine (Grant no TRIA-2015–1076-IMPROVE). The study by Luntamo et al. [46] was supported by grants from the Academy of Finland (grants 79787 and 207010), the Foundation for Pediatric Research in Finland, the Medical Research Fund of Tampere University Hospital, and Pfizer Inc (New York, NY). The study by Schmiegelow et al. [28] was funded by the European Union Framework 7 (STOPPAM, Tanzania) contract number: 200889. The study by Madanitsa et al.; [39] was funded by a grant from the European & Developing Countries Clinical Trials Partnership (Award Number IP.2007.31080.003 to FOfK), supplemented by funds from the Malaria in Pregnancy Consortium, which is funded through a grant by the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine (Award Number 46099 to FOfK). The study by Ashorn et al. [38] was supported by a grant to the University of California, from the Bill & Melinda Gates Foundation, the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, US Agency for International Development (Agreement No. AID-OAA-A-12–00005), the Academy of Finland (grant 252075) and the Medical Research Fund of Tampere University Hospital (grant 9M004). The study by Divala et al. [42] was funded by U.S. National Institutes of Health grant 5U01AI087624 to Miriam Laufer. The study by Moeller et al. [45] was financially supported by the Danish Council for Strategic Research, Innovationsfonden Denmark (grant 1309-00003B), the Villum Foundation (Centre for Stochastic Geometry and Advanced Bioimaging), the Lundbeck Foundation (R209-2015–3580 to CS), and the Laege Sofus Carl Emil Friis og Hustru Olga Doris Friis' scholarship (to CS). The study by Gutman et al. was financially supported by the US President's Malaria Initiative. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Agency for International Development or the other funders.

## Availability of data and materials

Data used in this manuscript are available upon request subject to approval by the original authors.

## Declarations

### Ethical approval and consent to participate

The study by Luntamo et al. [46] was approved by the College of Medicine Research and Ethics Committee, Malawi and the Ethical Committee of Pirkanmaa Hospital District, Finland. The study by Ashorn et al. [38] was approved by the College of Medicine Research and Ethics Committee, University of Malawi and the Ethics Committee of Pirkanmaa Hospital District, Finland. The study by Madanitsa et al. [39] obtained ethical approval from the Liverpool School of Tropical Medicine and the Malawian National Health Science Research Committee. The study by Divala et al. [42] was approved by the University of Maryland, Baltimore Institutional Review Board, University of Malawi, College of Medicine Research and Ethics Committee, and the Malawi Pharmacy, Medicines and Poisons Board. The study by Schmiegelow et al. [28] received ethical approval from the Tanzania Medical Research Coordinating Committee (reference number NIMR7HQ/R.8a/Vol. IX/688). The study by Moeller et al. [45] received ethical clearance from the Medical Research Coordinating Committee of the National Institute for Medical Research in Tanzania (reference NIMR/HQ/R.8a/Vol. IX/1717). The study by Gutman et al. was approved by the Centers for Disease Control and Prevention and University of Malawi College of Medicine.

### Consent for publication

The included studies were performed according to Good Clinical Practice guidelines and the ethical standards of the Helsinki Declaration, and written informed consent was obtained from all participants prior to participation in the studies.

### Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup>Tanga Medical Research Centre, National Institute for Medical Research, P. O. Box, 210, Tanga, Tanzania. <sup>2</sup>Kamuzu University of Health Sciences, Blantyre, Malawi. <sup>3</sup>Tampere Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. <sup>4</sup>University of Maryland School of Medicine, Baltimore, USA. <sup>5</sup>Malawi University of Science and Technology, Thyolo, Malawi. <sup>6</sup>Faculty of Medicine and Health Technology, Center for Child, Adolescent, and Maternal Health Research, Tampere University, Tampere, Finland. <sup>7</sup>Department of Paediatrics, Tampere University Hospital, Tampere, Finland. <sup>8</sup>Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, US Centers for Diseases Control and Prevention, Atlanta, GA, USA. <sup>9</sup>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. <sup>10</sup>Section of Global Health, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. <sup>11</sup>Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. <sup>12</sup>Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.

Received: 1 June 2022 Accepted: 23 September 2022

Published online: 12 October 2022

## References

- WHO. World malaria report 2021. Geneva, World Health Organization. <https://www.who.int/publications/i/item/9789240040496>. Accessed 20 Jan 2022.
- Briand V, Saal J, Ghafari C, Huynh B, Fievet N, Schmiegelow C, et al. Fetal growth restriction is associated with malaria in pregnancy: a prospective longitudinal study in Benin. *J Infect Dis*. 2016;214:417–25.
- Desai M, ter Kuile FO, Nosten F, McGready R, Asamo K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. *Lancet Infect Dis*. 2007;7:93–104.
- Schmiegelow C, Matondo S, Minja DTR, Resende M, Pehrson C, Nielsen BB, et al. *Plasmodium falciparum* infection early in pregnancy has profound consequences for fetal growth. *J Infect Dis*. 2017;216:1601–10.
- Landis SH, Lokomba V, Ananth CV, Atibu J, Ryder RW, Hartmann KE, et al. Impact of maternal malaria and under-nutrition on intrauterine growth restriction: a prospective ultrasound study in Democratic Republic of Congo. *Epidemiol Infect*. 2009;137:294–304.
- Kramer MS. The epidemiology of adverse pregnancy outcomes: an overview. *J Nutr*. 2003;133(Suppl 2):1592s–s1596.
- Zhang J, Merialdi M, Platt LD, Kramer MS. Defining normal and abnormal fetal growth: promises and challenges. *Am J Obstet Gynecol*. 2010;202:522–8.
- Francis JH, Permezel M, Davey MA. Perinatal mortality by birthweight centile. *Aust N Z J Obstet Gynaecol*. 2014;54:354–9.
- Glinianaia SV, Rankin J, Pearce MS, Parker L, Pless-Mulloli T. Stillbirth and infant mortality in singletons by cause of death, birthweight, gestational age and birthweight-for-gestation, Newcastle upon Tyne 1961–2000. *Paediatr Perinat Epidemiol*. 2010;24:331–42.
- Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, et al. Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis. *Lancet*. 2013;382:417–25.
- Moraitis AA, Wood AM, Fleming M, Smith GCS. Birth weight percentile and the risk of term perinatal death. *Obstet Gynecol*. 2014;124:274–83.
- Vangen S, Stoltenberg C, Skjaerven R, Magnus P, Harris JR, Stray-Pedersen B. The heavier the better? Birthweight and perinatal mortality in different ethnic groups. *Int J Epidemiol*. 2002;31:654–60.
- Crispi F, Miranda J, Gratacós E. Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease. *Am J Obstet Gynecol*. 2018;218(Suppl 2):S869–79.

14. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. *N Engl J Med*. 2008;359:61–73.
15. Osmond C, Barker DJ. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. *Environ Health Perspect*. 2000;108(Suppl 3):545–53.
16. Buck Louis GM, Grewal J, Albert PS, Sciscione A, Wing DA, Grobman WA, et al. Racial/ethnic standards for fetal growth: the NICHD fetal growth studies. *Am J Obstet Gynecol*. 2015;213:449.e1–e41.
17. Visser GHA, Nicholson WK, Barnea ER, Ramasauskaite D, Nassar AH. FIGO position paper on reference charts for fetal growth and size at birth: which one to use? *Int J Gynaecol Obstet*. 2021;152:148–51.
18. Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet*. 2014;384:857–68.
19. Kiserud T, Puggio G, Carroli G, Widmer M, Carvalho J, Neerup Jensen L, et al. The World Health Organization fetal growth charts: a multinational longitudinal study of ultrasound biometric measurements and estimated fetal weight. *PLoS Med*. 2017;14:e1002220.
20. Anderson NH, Sadler LC, McKinlay CJD, McCowan LME. INTERGROWTH-21st vs customized birthweight standards for identification of perinatal mortality and morbidity. *Am J Obstet Gynecol*. 2016;214:509.e1–e7.
21. Francis A, Hugh O, Gardosi J. Customized vs INTERGROWTH-21(st) standards for the assessment of birthweight and stillbirth risk at term. *Am J Obstet Gynecol*. 2018;218(Suppl 2):S692–9.
22. Heude B, Le Guern M, Forhan A, Scherdel P, Kadawathagedara M, Dufour MN, et al. Are selection criteria for healthy pregnancies responsible for the gap between fetal growth in the French national Elfe birth cohort and the Intergrowth 21st fetal growth standards? *Paediatr Perinat Epidemiol*. 2019;33:47–56.
23. Lavin T, Nedkoff L, Preen D, Theron G, Pattinson RC. INTERGROWTH-21st v local South African growth standards (theron-thompson) for identification of small-for-gestational-age fetuses in stillbirths: a closer look at variation across pregnancy. *S Afr Med J*. 2019;109:519–25.
24. Liu S, Metcalfe A, León JA, Sauve R, Kramer MS, Joseph KS. Evaluation of the INTERGROWTH-21st project newborn standard for use in Canada. *PLoS ONE*. 2017;12:e0172910.
25. Poon LC, Tan MY, Yerlikaya G, Syngelaki A, Nicolaidis KH. Birth weight in live births and stillbirths. *Ultrasound Obstet Gynecol*. 2016;48:602–6.
26. Sletner L, Kiserud T, Vangen S, Nakstad B, Jenum AK. Effects of applying universal fetal growth standards in a Scandinavian multi-ethnic population. *Acta Obstet Gynecol Scand*. 2018;97:168–79.
27. Yao F, Miao H, Li B, Wu Y, Zhao Q. New birthweight percentiles by sex and gestational age in Southern China and its comparison with the INTERGROWTH-21st Standard. *Sci Rep*. 2018;8:7567.
28. Schmiegelow C, Scheike T, Oesterholt M, Minja D, Pehrson C, Magistrado P, et al. Development of a fetal weight chart using serial trans-abdominal ultrasound in an East African population: a longitudinal observational study. *PLoS ONE*. 2012;7:e44773.
29. Robinson HP. Sonar measurement of fetal crown-rump length as means of assessing maturity in first trimester of pregnancy. *BMJ*. 1973;4:28–31.
30. Hadlock FP, Shah YP, Kanon DJ, Lindsey JV. Fetal crown-rump length: reevaluation of relation to menstrual age (5–18 weeks) with high-resolution real-time US. *Radiology*. 1992;182:501–5.
31. Chitty LS, Altman DG, Henderson A, Campbell S. Charts of fetal size: 2 Head measurements. *Br J Obstet Gynaecol*. 1994;101:35–43.
32. Papageorgiou AT, Ohuma EO, Altman DG, Todros T, Cheikh Ismail L, Lambert A, et al. International standards for fetal growth based on serial ultrasound measurements: the fetal growth longitudinal study of the INTERGROWTH-21st Project. *Lancet*. 2014;384:869–79.
33. Stirnemann J, Villar J, Salomon LJ, Ohuma E, Ruyan P, Altman DG, et al. International estimated fetal weight standards of the INTERGROWTH-21(st) Project. *Ultrasound Obstet Gynecol*. 2017;49:478–86.
34. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements—a prospective study. *Am J Obstet Gynecol*. 1985;151:333–7.
35. Verhoeff FH, Brabin BJ, van Buuren S, Chimsuku L, Kazembe P, Wit JM, et al. An analysis of intra-uterine growth retardation in rural Malawi. *Eur J Clin Nutr*. 2001;55:682–9.
36. Landis SH, Ananth CV, Lokomba V, Hartmann KE, Thorp JM Jr, Horton A, et al. Ultrasound-derived fetal size nomogram for a sub-Saharan African population: a longitudinal study. *Ultrasound Obstet Gynecol*. 2009;34:379–86.
37. Zakama AK, Weekes T, Kajubi R, Kakuru A, Ategeka J, Kanya M, et al. Generation of a malaria negative Ugandan birth weight standard for the diagnosis of small for gestational age. *PLoS ONE*. 2020;15:e0240157.
38. Ashorn P, Alho L, Ashorn U, Cheung YB, Dewey KG, Harjunmaa U, et al. The impact of lipid-based nutrient supplement provision to pregnant women on newborn size in rural Malawi: a randomized controlled trial. *Am J Clin Nutr*. 2015;101:387–97.
39. Madanitsa M, Kalilani L, Mwapa V, van Eijk AM, Khairallah C, Ali D, et al. Scheduled intermittent screening with rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine versus intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy in Malawi: an open-label randomized controlled trial. *PLoS Med*. 2016;13:e1002124.
40. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898.
41. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014. [https://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Accessed 20 Jan 2022.
42. Divala TH, Mungwira RG, Mawindo PM, Nyirenda OM, Kanjala M, Ndaferankhande M, et al. Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. *Lancet Infect Dis*. 2018;18:1097–107.
43. Villar J, Altman DG, Purwar M, Noble JA, Knight HE, Ruyan P, et al. The objectives, design and implementation of the INTERGROWTH-21st project. *BJOG*. 2013;120(Suppl 2):9–26.
44. Kontopantelis E, Reeves D. A short guide and a forest plot command (ipdforest) for one-stage meta-analysis. *Stata J*. 2013;13:574–87.
45. Moeller SL, Nyengaard JR, Larsen LG, Nielsen K, Bygbjerg IC, Msemu OA, et al. Malaria in early pregnancy and the development of the placental vasculature. *J Infect Dis*. 2019;220:1425–34.
46. Luntamo M, Kulmala T, Cheung YB, Maleta K, Ashorn P. The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. *Trop Med Int Health*. 2013;18:386–97.
47. Ott WJ. Intrauterine growth retardation and preterm delivery. *Am J Obstet Gynecol*. 1993;168:1710–5.
48. Salomon LJ, Bernard JP, Ville Y. Estimation of fetal weight: reference range at 20–36 weeks' gestation and comparison with actual birth-weight reference range. *Ultrasound Obstet Gynecol*. 2007;29:550–5.
49. Papageorgiou AT, Kennedy SH, Salomon LJ, Altman DG, Ohuma EO, Stones W, et al. The INTERGROWTH-21(st) fetal growth standards: toward the global integration of pregnancy and pediatric care. *Am J Obstet Gynecol*. 2018;218:S630–s640.
50. Hocquette A, Durox M, Wood R, Klungsøyr K, Szamatulska K, Berrut S, et al. International versus national growth charts for identifying small and large-for-gestational age newborns: a population-based study in 15 European countries. *Lancet Reg Health Eur*. 2021;8:100167.
51. Pimenta JRR, Grandi C, Aragon DC, Cardoso VC. Comparison of birth weight, length, and head circumference between the BRISA-RP and Intergrowth-21st cohorts. *J Pediatr (Rio J)*. 2020;96:511–9.
52. Gamble C, Ekwari PJ, Garner P, ter Kuile FO. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomised controlled trials. *PLoS Med*. 2007;4:e107.
53. Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. *Cochrane Database Syst Rev*. 2014. <https://doi.org/10.1002/14651858.CD000169.pub3>.
54. Mirghani HM, Weerasinghe S, Ezimokhai M, Smith JR. Ultrasonic estimation of fetal weight at term: an evaluation of eight formulae. *J Obstet Gynaecol Res*. 2005;31:409–13.

55. Merialdi M, Caulfield LE, Zavaleta N, Figueroa A, Costigan KA, Dominici F, et al. Fetal growth in peru: comparisons with international fetal size charts and implications for fetal growth assessment. *Ultrasound Obstet Gynecol.* 2005;26:123–8.
56. Overpeck MD, Hediger ML, Zhang J, Trumble AC, Klebanoff MA. Birth weight for gestational age of Mexican American infants born in the United States. *Obstet Gynecol.* 1999;93:943–7.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

